Further, because KRASG12C mutations only account for 3% of CRC cases, there is an urgent medical need to treat CRC patients harboring other KRAS mutations, including patients with G12D (30.1%), G12V (24.2%), G12R (2.1%), or other (19.6%) mutations (7). Here, KRAS is linked to colorectal carcinoma.